Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

Abstract To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA originator, after switching to them....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Linda Cingolani, Brigida Barberio, Fabiana Zingone, Antonio Ferronato, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Piera Melatti, Alessandro Gubbiotti, Davide Massimi, Cesare Casadei, Renata D’Incà, Edoardo Vincenzo Savarino
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/e1df2d0bb34a4efe88e26cf19e6d58b1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/e1df2d0bb34a4efe88e26cf19e6d58b1

Ejemplares similares